033270 — Korea United Pharm Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapContrarian

Annual income statement for Korea United Pharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	215,950	221,040	262,522	278,943	288,707
Cost of Revenue
Gross Profit	125,192	122,660	145,288	158,977	163,965
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	175,824	187,815	214,309	224,641	256,639
Operating Profit	40,126	33,225	48,213	54,302	32,068
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	35,650	39,483	53,425	60,084	46,089
Provision for Income Taxes
Net Income After Taxes	26,613	28,649	45,275	48,262	32,453
Net Income Before Extraordinary Items
Net Income	26,613	28,649	45,275	48,262	32,453
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	26,613	28,649	45,275	48,262	32,453
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,789	1,913	3,025	3,313	3,388
Dividends per Share